Ethypharm's New Treatment Strategy for Inflammatory Bowel Disease in China

Ethypharm's Expansion in China

Ethypharm, a well-known pharmaceutical company, has recently acquired a new form of Mesalazine from Jiangsu Anbison Pharmaceutical. This acquisition allows Ethypharm to introduce a suppository form of Mesalazine into the Chinese market, which has been primarily dominated by oral and topical treatments for Inflammatory Bowel Diseases (IBD).

The acquisition is part of Ethypharm's broader strategy to grow in significant global markets, including China and the five major European countries. By expanding its product portfolio, Ethypharm aims to meet the growing demand for diverse and effective treatments for conditions like ulcerative colitis and Crohn's disease.

What is Mesalazine?

Mesalazine, also known as mesalamine, is a medication that helps reduce inflammation in the gut, making it beneficial for treating IBD. It is particularly effective in managing symptoms like diarrhea, abdominal pain, and rectal bleeding. Traditionally, Mesalazine has been available in oral and topical forms.

The new suppository form of Mesalazine offers additional benefits by providing targeted delivery of the medication directly to the lower part of the digestive tract. This can enhance the drug’s effectiveness and reduce potential side effects that might occur with systemic absorption from oral forms.

The Importance of Targeted Drug Delivery

The targeted drug delivery provided by suppositories can offer several advantages. By delivering Mesalazine directly to the affected area, the dosage can be minimized while maximizing its impact. This targeted approach is particularly useful for patients who have severe inflammation localized in the lower rectum or sigmoid colon.

Moreover, suppositories can bypass the digestive system, which can be beneficial for patients who experience gastrointestinal discomfort or have trouble swallowing pills.

Ethypharm's Growth in the Chinese IBD Market

Since its introduction to the Chinese market in 1997, Ethypharm's oral Mesalazine, branded as Etiasa®, has garnered approximately 30% of the market share. This success demonstrates the strong acceptance and trust in Ethypharm's products among Chinese patients and healthcare professionals.

China is the third-largest market for Mesalazine worldwide, and there's a significant need for various forms of the medication. By incorporating the suppository form, Ethypharm can better address the diverse needs of IBD patients in China, strengthening its market presence even further.

Commitment to Quality and Patient Care

Ethypharm is dedicated to delivering high-quality medications that meet the rigorous standards of international healthcare authorities. This commitment ensures that patients receive effective and safe treatments for their conditions.

In addition to providing essential medicines, Ethypharm collaborates closely with healthcare professionals to ensure that its products are used appropriately, ultimately aiming to improve patient outcomes and quality of life.

Global Impact and Future Outlook

With operations in 68 countries and strategic partnerships across multiple regions, Ethypharm is well-positioned to continue its growth. The company focuses on several therapeutic areas, including central nervous system disorders, hospital care, and internal medicine.

The acquisition of the new Mesalazine form is a testament to Ethypharm's strategy of growth through both organic development and strategic acquisitions. This approach allows the company to expand its product offerings while maintaining a high standard of care.

Ethypharm's Vision

Denis Delval, President and CEO of Ethypharm, emphasizes that this acquisition is a significant step forward for the company's growth strategy. By offering a complete portfolio of Mesalazine forms, Ethypharm is better equipped to meet the evolving needs of patients and healthcare providers in China.

This strategic move reinforces Ethypharm's dedication to providing essential medicines that improve patient lives and underscores its commitment to being a leader in the pharmaceutical industry.